For the year ending 2025-12-31, ALGS had -$18,694K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -24,193 |
| Accretion of discount on investments | 2,188 |
| Non cash lease expense | 1,875 |
| Change in fair value of 2023 common warrants | -60,184 |
| Depreciation expense | 930 |
| Stock-based compensation including espp | 5,044 |
| Accounts payable | 1,411 |
| Accrued liabilities | -2,031 |
| Operating lease liabilities | -3,112 |
| Deferred revenue | -151 |
| Other assets | -96 |
| Net cash and cash equivalents used in operating activities | -82,503 |
| Maturities of short-term investments | 127,500 |
| Purchase of short-term investments | 164,889 |
| Purchases of property and equipment | -437 |
| Net cash and cash equivalents used in investing activities | -37,826 |
| Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with pipe offering, net of costs | 101,345 |
| Payments on finance lease | 14 |
| Proceeds from the espp purchase | 304 |
| Net cash and cash equivalents provided by financing activities | 101,635 |
| Net decrease in cash, cash equivalents, and restricted cash | -18,694 |
| Cash, cash equivalents, and restricted cash, beginning of period | 37,107 |
| Cash, cash equivalents, and restricted cash, end of period | 18,413 |
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)